PortalPublikationenHistone methyltransferase SETDB1 contributes to melanoma tum...

Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target

Standard

Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target. / Orouji, Elias; Federico, Aniello; Larribère, Lionel; Novak, Daniel; Lipka, Daniel B; Assenov, Yassen; Sachindra, Sachindra; Hüser, Laura; Granados, Karol; Gebhardt, Christoffer; Plass, Christoph; Umansky, Viktor; Utikal, Jochen.

in: INT J CANCER, Jahrgang 145, Nr. 12, 15.12.2019, S. 3462-3477.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Orouji, E, Federico, A, Larribère, L, Novak, D, Lipka, DB, Assenov, Y, Sachindra, S, Hüser, L, Granados, K, Gebhardt, C, Plass, C, Umansky, V & Utikal, J 2019, 'Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target', INT J CANCER, Jg. 145, Nr. 12, S. 3462-3477. https://doi.org/10.1002/ijc.32432

APA

Orouji, E., Federico, A., Larribère, L., Novak, D., Lipka, D. B., Assenov, Y., Sachindra, S., Hüser, L., Granados, K., Gebhardt, C., Plass, C., Umansky, V., & Utikal, J. (2019). Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target. INT J CANCER, 145(12), 3462-3477. https://doi.org/10.1002/ijc.32432

Vancouver

Orouji E, Federico A, Larribère L, Novak D, Lipka DB, Assenov Y et al. Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target. INT J CANCER. 2019 Dez 15;145(12):3462-3477. https://doi.org/10.1002/ijc.32432

Bibtex

@article{8b4e32b0ffc14176ab37b76ec00cd837,
title = "Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target",
abstract = "Alterations in histone modifications play a crucial role in the progression of various types of cancer. The histone methyltransferase SETDB1 catalyzes the addition of methyl groups to histone H3 at lysine 9. Here, we describe how overexpression of SETDB1 contributes to melanoma tumorigenesis. SETDB1 is highly amplified in melanoma cells and in the patient tumors. Increased expression of SETDB1, which correlates with SETDB1 amplification, is associated with a more aggressive phenotype in in vitro and in vivo studies. Mechanistically, SETDB1 implements its effects via regulation of thrombospondin 1, and the SET-domain of SETDB1 is essential for the maintenance of its tumorigenic activity. Inhibition of SETDB1 reduces cell growth in melanomas resistant to targeted treatments. Our results indicate that SETDB1 is a major driver of melanoma development and may serve as a potential future target for the treatment of this disease.",
author = "Elias Orouji and Aniello Federico and Lionel Larrib{\`e}re and Daniel Novak and Lipka, {Daniel B} and Yassen Assenov and Sachindra Sachindra and Laura H{\"u}ser and Karol Granados and Christoffer Gebhardt and Christoph Plass and Viktor Umansky and Jochen Utikal",
note = "{\textcopyright} 2019 UICC.",
year = "2019",
month = dec,
day = "15",
doi = "10.1002/ijc.32432",
language = "English",
volume = "145",
pages = "3462--3477",
journal = "INT J CANCER",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "12",

}

RIS

TY - JOUR

T1 - Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target

AU - Orouji, Elias

AU - Federico, Aniello

AU - Larribère, Lionel

AU - Novak, Daniel

AU - Lipka, Daniel B

AU - Assenov, Yassen

AU - Sachindra, Sachindra

AU - Hüser, Laura

AU - Granados, Karol

AU - Gebhardt, Christoffer

AU - Plass, Christoph

AU - Umansky, Viktor

AU - Utikal, Jochen

N1 - © 2019 UICC.

PY - 2019/12/15

Y1 - 2019/12/15

N2 - Alterations in histone modifications play a crucial role in the progression of various types of cancer. The histone methyltransferase SETDB1 catalyzes the addition of methyl groups to histone H3 at lysine 9. Here, we describe how overexpression of SETDB1 contributes to melanoma tumorigenesis. SETDB1 is highly amplified in melanoma cells and in the patient tumors. Increased expression of SETDB1, which correlates with SETDB1 amplification, is associated with a more aggressive phenotype in in vitro and in vivo studies. Mechanistically, SETDB1 implements its effects via regulation of thrombospondin 1, and the SET-domain of SETDB1 is essential for the maintenance of its tumorigenic activity. Inhibition of SETDB1 reduces cell growth in melanomas resistant to targeted treatments. Our results indicate that SETDB1 is a major driver of melanoma development and may serve as a potential future target for the treatment of this disease.

AB - Alterations in histone modifications play a crucial role in the progression of various types of cancer. The histone methyltransferase SETDB1 catalyzes the addition of methyl groups to histone H3 at lysine 9. Here, we describe how overexpression of SETDB1 contributes to melanoma tumorigenesis. SETDB1 is highly amplified in melanoma cells and in the patient tumors. Increased expression of SETDB1, which correlates with SETDB1 amplification, is associated with a more aggressive phenotype in in vitro and in vivo studies. Mechanistically, SETDB1 implements its effects via regulation of thrombospondin 1, and the SET-domain of SETDB1 is essential for the maintenance of its tumorigenic activity. Inhibition of SETDB1 reduces cell growth in melanomas resistant to targeted treatments. Our results indicate that SETDB1 is a major driver of melanoma development and may serve as a potential future target for the treatment of this disease.

U2 - 10.1002/ijc.32432

DO - 10.1002/ijc.32432

M3 - SCORING: Journal article

C2 - 31131878

VL - 145

SP - 3462

EP - 3477

JO - INT J CANCER

JF - INT J CANCER

SN - 0020-7136

IS - 12

ER -